Abstract
In current China’s National Reimbursement Drug List (NRDL) negotiation, when submitting cost-effectiveness analysis evidence, Volume-based Procurement (VBP) price is referenced for comparator if comparator is off-patent drug with generics. Our study aims to explore whether it is reasonable to reference VBP price of comparator in innovative drugs NRDL negotiation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
